Candel Therapeutics, Inc. (CADL)

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics to Present at September Investor Conferences

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up

Candel Therapeutics: Getting Closer, And Building Out More Paths

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston